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Abstract
Objective: To compare fecal transplant and vancomycin in the treatment of recurrent
clostridium difficile to determine which has the higher cure rate. Design: Systematic
literature review. Methods: Pubmed, Google Scholar, and TRIP database using the
search terms “recurrent clostridium difficile.” Filters were implemented in the Pubmed
database including: randomized control trials, English, and published in the past 5
years. Records were screened for RCT with fecal transplant and full-text. Results: van
Nood et al. revealed an initial cure rate of 81% for the infusion group, and a re-treated
cure rate of 94%, compared to the vancomycin alone group of 31% cure rate and the
vancomycin plus bowel lavage group of 23% cure rate. Cammarota et al. determined an
initial cure rate of 65% for the infusion group, and a re-treated cure rate of 90%,
compared to the vancomycin only group of 26% cure rate. Conclusion: An initial
abbreviated dose of vancomycin at the start of fecal transplant has a significantly higher
cure rate in treating recurrent clostridium difficile infections when compared to standard
vancomycin therapy.

Introduction
Clostridium difficile (C. difficile), a gram-positive, anaerobic bacillus bacterium, is
spread via the fecal-oral route, and is known for it’s colonization of the gastrointestinal
tract, commonly after a regimen of antibiotic therapy has been used, altering the normal
gut flora of the patient.1,2,3 In the United States, C. difficile infection is the most common
healthcare associated infection, and is increasing in both frequency and severity of
infection.3,2 High-risk populations include 65 years or older, less than 1 year old with
underlying condition, male gender, increased hospitalization time, and recent
antimicrobial therapy.3 Known antibiotics associated with the development of C. difficile
include fluoroquinolones, clindamycin, penicillins, and cephalosporins.4 According to
Barbut et al, C. difficile infections may cost up to $3.2 billion per year, along with
causing an estimated 15,000 – 20,000 deaths annually in the United States alone.5
There are seven stages of C. diff infection, including: Carrier stage, C. difficileassociated diarrhea, C. difficile-associated Colitis, Pseudomembranous Colitis,
Fulminant Colitis, Recurrent Clostridium difficile infection (CDI), and Extracolonic
Infections.3 The studies included in this systematic literature review are looking at
recurrent Clostridium difficile primarily, which involves the complete resolution of
symptoms associated with the initial occurrence of C. difficile after therapy, followed by
a relapse of symptoms and C. difficile infection.4 In approximately 10 – 25% of patients
who have completed C. difficile therapy, recurrence will occur.4 Symptoms associated
with recurrent C. difficile include the cardinal symptom of watery diarrhea with at least 3
stools within 24 hours, abdominal pain, low-grade fever, nausea, and anorexia.4
Diagnosis of CDI infection is primarily clinical, with a history including recent
antimicrobial use and diarrhea.3 Laboratory tests are performed on unformed stool
samples.3The best sample for diagnosis consists of watery or loose stool, as fresh as

possible. Culture may be performed, but is not routinely done due to the cost and
clinician experience needed. If culture is performed, it is recommended to do so with the
assistance of infectious disease specialist and/or gastroenterology specialists. There is
a variety of toxin assays that may be used for the detection of Clostridium difficile,
including cell culture neutralization assay, which is highly sensitive and specific, but
time-consuming and labor-intensive. Immunoassay detects both toxins A and B, utilizing
methods such as enzyme immunoassay and immunochromatography. Nucleic Acid
Amplication, with sensitivity of 90-100% and specificity of 94-100%, are the most recent
methods, able to identify genes of Clostridium difficile. Latex agglutination assay detects
glutamate dehydrogenase, but is not used routinely. If there are normal stool laboratory
test results with high suspicion, then sigmoidoscopy and colonoscopy may be used for
diagnosis.3
Initial treatment for a patient with C. difficile begins with the cessation of any
current antibiotics that the patient may be taking, if possible.1 After stopping the
offending medication, current treatment options for recurrent Clostridium difficile include
primarily a course of vancomycin or fixoxamycin; however, fecal transplant is now
becoming a viable option. Standard vancomycin for the treatment of Clostridium difficile
is 500 mg PO QID.3 According to Goudarzi et al., approximately 25% of patients with C.
difficile who have been treated with either metronidazole or vancomycin experience
recurrent symptoms, within 4 weeks of completing therapy.3
The basis of fecal microbiota transplant involves the restoration and recolonization of healthy, normal gut flora in the affected gastrointestinal tract due to C.
difficile invasion or irritable bowel disease, along with other various causes of altered
gut flora. Fecal transplant implements a donor that undergoes extensive screening and
testing. The donors are screened via a questionnaire on such things as medical history,
lifestyle habits, antibiotic use in the past 6 months, intestinal diseases and/or symptoms.
The donor stool is screened for C. difficile enteric bacteria, protozoa, helminthes, as well
as drug resistant bacteria. The donors blood is also tested for hepatitis A, B and C, HIV1 and HIV-2 antibodies, Epstein-Barr virus, Treponema pallidm, Strongyloides
stercoralis and Entamoeba histolytica. First the feces is collected from the donors on the
day of infusion and then diluted with 500 mL of sterile saline (0.9%) and blended. Finally
the supernatant was strained and stored in a sterile container until infusion. The feces
can be given to the patient via nasogastric tube, colonoscopy, enema, and via
capsulated pill. Of these routes, for patients with recurrent C. difficile, colonoscopic fecal
microbial transplant is superior to nasogastric fecal transplant in regards to the cure rate
of this infection.6 Diarrhea, constipation, abdominal cramping, gurgling, and gas are the
adverse effects that have been present after a fecal microbial transplant, although
considered brief and minor occurances.6
Infection control is an important aspect throughout the treatment of a CDI
infection. One of the most important aspects of CDI prevention is hand washing with
both soap and water, which is more effective compared to an alcohol based solution.3,1
Appropriate contact precaution including wearing gloves and gowns when working with
these patients is important to reduce the spread as well.

Clinical Question:
In patients over 18 years old who have developed recurrent Clostridium difficile, is fecal
transplantation compared to vancomycin more efficacious in the treatment of recurrent
Clostridium difficile infection?

Methods
In October of 2015 the PubMed
database was searched using the terms
recurrent clostridum difficile, which
yielded 669 results initially. Searches of
Google Scholar and TRIP databases
produced no additional articles. These
results were then limited to English only
and randomized control trials within the
past 5 years. This reduced the number
of results to 10. Next these trials were
reviewed and only those that involved
fecal microbiota transplant were chosen.
There were a total of three trials that met
these criteria. Of the three trials only two
looked at fecal microbiota transplant v.s.
vancomycin. The third trial was a pilot
RCT assessing administration routes for
fecal microbiota transplant and was
eliminated. The two articles meeting
these criteria were Duodenal Infusion of
Donor Feces for Recurrent Closridium
difficile. Van Nood et al and Randomised
Figure 1. PRISMA Flow Diagram.
clinical trial: faecal microbiota transplantation by
colonoscopy vs. vancomycin for the treatment of
recurrent Clostridium difficile infection.
Cammarota et al. Figure 1 provides a visual PRISMA flow diagram of this process.

Results
Study #1
Duodenal Infusion of Donor Feces for Recurrent Closridium difficile. Els van Nood et al.7

Study Objective
To determine if fecal transplant with vancomycin for the treatment options for recurrent
Clostridium difficile is more effective compared to vancomycin alone or vancomycin with
bowel lavage.

Study Design
In this open label, randomized controlled trial, 43 patients were divided into three
treatment groups: initial abbreviated vancomycin regimen with bowel lavage and donor
feces, standard vancomycin regimen with bowel lavage, and standard vancomycin
regimen. The Table 1 demonstrates the study population via inclusion and exclusion
criteria. The feces donor criteria are outlined in Table 2 that was given to the fecal
transplant group via nasoduodenal tube. If the fecal transplant group required a second
treatment, the second infusion was performed using a different donor.

Table 1. Patient Inclusion and Exclusion Criteria
Inclusion Criteria

Exclusion Criteria

≥ 18 years old
Life expectancy ≥ 3 months
Relapse of C. difficile infection
after at least one course of
adequate antibiotic therapy

Prolonged immunodeficiency due to recent
chemotherapy
HIV infection with a CD4 count < 240
Prolonged use of prednisolone at a dose of ≥ 60
mg/day
Pregnancy
Use of antibiotics other than for treatment of C.
difficile infection at baseline
Admission to an intensive care unit
Need for vasopressor medication

Table 2. Feces Donor Inclusion and Exclusion Criteria
Inclusion Criteria Exclusion Criteria
<60 years of age

History of parasites, C. difficile, and enteropathogenic bacteria,
HIV, Human T-cell lymphotropic virus types 1 and 2, Hepatitis A,
B, and C, Cytomegalovirus, Epstein-Barr virus
Recent illness

Study Results
The infusion group initially had an 81% (13/16 patients) cure rate, that increased
to 94% (15/16 patients) after 3 more participants were re-treated with an additional
infusion from a different donor. The vancomycin alone group had a 31% (4/13 patients)
cure rate. The vancomycin plus bowel prep group had a 23% (3/13 patients) cure rate.
Adverse events reported immediately after infusion were 94% of patients reported
diarrhea, 31% cramping, and 19% belching. All of the effects were self-limiting and
resolved within 3 hours of presentation. During the follow up visit 19% of patients
reported constipation. No adverse events were reported in the other two groups. This

study was terminated early by the monitoring board due to a high number of relapse in
both of the vacomycin groups.
Number Needed to Treat (NNT): 1.58. We chose the use the vancomycin alone group
as the control to determine the number needed to treat compared to the infusion group.
The NNT may be interpreted as 1.58 patients must be treated over a period of 1 year to
prevent one recurrence of CDI.
Study Critique
There was no comparison between the standard vancomycin regimen with bowel
lavage to the standard vancomycin regimen groups. Both groups were compared to the
initial vancomycin regimen with bowel lavage and donor feces, but not to each other.
The small population size is also a disadvantage of this study resulting in a possible
type II error or failing to show statistical significance when there is actually a difference
between the two study groups. This study also terminated early due to high recurrence
rates of the vancomycin group..For patients that were in the vancomycin groups, if their
therapy failed, they were able to choose to have the donor feces given off protocol,
which adds confounding variables to this study.
Study #2
Randomized clinical trial: faecal microbiota transplantation by colonoscopy vs.
vancomycin for the treatment of recurrent Clostridium difficile infection. Cammarota et
al8
Study Objective
To investigate if fecal transplantation is more effective at treating recurrent Clostridium
difficile compared to vancomycin standard therapy.
Study Design
Open label, blocked randomized clinical trial comparing faecal microbiota
transplantation with vancomycin treatment to vancomycin only treatment. Blocked
randomized clinical trial refers to the addition of an external person, which is not
involved in the study, and a random number generator software that uses random
subgroup “block” sizes of 6 in addition to a ratio, which reduces variability within groups
and reduces likelihood of confounding8. All patients who met the inclusion and exclusion
criteria as outlined in Table 3, began the study with a three-day abbreviated treatment of
vancomycin (125 mg by month four times a day). At day 2 and 3, the fecal transplant
group also had a bowel lavage. At day four, they then either continued with the
vancomycin regimen, or stopped the vancomycin and began the first faecal infusion
from a fecal donor that met the inclusion and exclusion criteria as outlined in Table 4.
The vancomycin only treatment group continued with the 125 mg until day 11, when
they switched to vancomycin pulse regimen (125-500 mg/day every 2-3 days). Patients
that were diagnosed with pseudomembranous colitis were given a fecal infusion every 3
days, and patients in the fecal transplant group who relapsed after the first fecal
transplant, were given a second fecal transplant by a different donor within 1 week.

Table 3. Patient Inclusion and Exclusion Criteria
Inclusion Criteria

Exclusion Criteria

≥18 years of age
Life expectancy ≥ 3
months
Recurrence of C. difficile
after one or more courses
of specific antibiotic
therapy
Believed able to undergo
colonoscopy

Prolonged immunodeficiency due to recent chemotherapy
HIV infection
Prolonged use of steroids
Pregnancy
Use of antibiotics other than metronidazole, vancomycin
or fidaxomicin at baseline
Admission to an intensive care unit
Requirement for vasoactive drugs
Other infectious causes of diarrhea

Table 4. Feces Donor Inclusion and Exclusion Criteria
Inclusion Criteria Exclusion Criteria
Healthy
volunteers < 50
years of age,
preferable the
patient’s relatives
or intimates

Antibiotics taken within the last 6 months
Exhibited significant intestinal symptoms of other intestinal
diseases
Lifestyle associated with increased risk for contracting infections
Recent (≤3 month) travels in tropical areas
New sexual relationship in the last 6 months
Recent needlestick accident
Previous reception of blood products
Body tattoos
Gastrointestinal diseases or complaints
Family history of gastrointestinal cancer or inflammatory bowel
disease
Systemic diseases such as diabetes or neurological disorder
Use of drugs that could be excreted in feces with potential risk for
the recipients

Study Results

Table 5. Overview of Studies
Cammarota et al.

van Nood et al.
Population

Referring hospitals in collaboration with the
Academic Medical Center in Amsterdam

The A. Gemelli University
Hospital in Rome.

Primary
Interest

To compare fecal transplant with an
abbreviated vancomycin treatment to
vancomycin standard therapy and vancomycin
with bowel lavage in the treatment of recurrent
Clostridium difficile

To compare fecal
transplant with an
abbreviated vancomycin
treatment to vancomycin
standard treatment in the
treatment of recurrent
Clostridium difficile

Fecal
Transplant

Vancomycin
Only

Vancomycin +
Bowel Lavage

Fecal
Transplant

Vancomycin
Only

Patients, N

16

13

13

20

19

Gender

50% F,
50% M

54% F, 46% M

23% F, 77% M

60% F,
40% M

58% F, 42%
M

Average Age

73 +/- 13

66 +/- 14

69 +/- 16

71

75

Randomized

Yes

Yes

Analysis

Intention to treat

Intention to treat

Definition of
Cure

10 weeks of no diarrhea

10 weeks of no diarrhea

Blinding

Preceptors and participants were not blinded,
but the assessors of “cured” were blinded.

No

The infusion group initially had a 65% (13/20 patients) cure rate that increased to
90% (18/20 patients) after multiple infusions. Two of the patients in this group died
before the end of the study due to C. diff complications. The vancomycin only treatment
was 26% effective with 5 of the 19 cured after treatment. Two of the patients in this
group died before the end of the study due to C. diff complications as well. Overall
intention to treat analysis of the transplant group compared to the vancomycin group
demonstrated that the infusion group was superior and statistically significant with
p<0.0001 (90% vs. 26%). After one year an interim analysis was done revealing a
significantly higher efficacy than vancomycin and the study was stopped with a total of
only 39 enrolled patients. Immediately after infusion 94% experienced diarrhea and 60%
bloating/cramping, all symptoms resolved within 12 hrs. There were no adverse events
reported in the vancomycin group.
Number Needed to Treat (NNT): 1.57. We used the vancomycin only treatment group
and the faecal microbiota transplantation with vancomycin treatment group to determine
the NNT. The NNT may be interpreted as 1.57 patients must be treated over a period of
1 year to prevent recurrence of CDI.
Study Critique
Patients involved in infusion group were able to repeat the fecal transplant as many
times as needed to improve the cure rate. For the patients with pseudomembranous
colitis, the fecal transplant frequency increased to an infusion every 3 days until cured,
although the study does not address the maximum time or number of infusions that
were done before the patients were cured. The cost and risk of complications for the
treatment groups was not discussed either. The vancomycin group may or may not
have had patients with pseudomembranous colitis, since this was not determined via
colonscopy as it was for the fecal transplant group. The small population size is a
disadvantage of this study. The early termination of the study caused the study to fall
short of the projected power goal of 90% with 41 patients per group.

Discussion
The mainstay of treatment for C.difficile infection since the 1970’s has been
metronidazole and oral vancomycin with the addition of findaxomicin in 2011.9 Phase
three clinical trials showed a risk of recurrent infection around 25% with vancomycin.10
Given the relatively high mortality, morbidity, and recurrence rates of this infection the
investigation of other viable treatment options is warranted.
An overview of these two studies may provide some insight into the efficacy of this
unusual treatment. Both the Els van Nood et al and the Cammarota et al studies were

open-label randomized trials, although the Cammarota et al study did not assign a
control group. The recipient group inclusion/exclusion criteria for the two studies were
nearly identical, although the donor
criteria differed heavily (Tables 1 and
3). The inclusion/exclusion criteria for
the donors were very different and
are outlined in tables 2 and 4. The
treatment protocols were very similar
but varied slightly between studies.
For obvious reasons, neither study
could blind the patients or the
treating clinicians although van Nood
et al did use a masked committee to
determine which patients were
cured. Cammarota et al study used a lower 125mg dose of vancomycin compared to
the 500mg dose used by Els van Nood et al study. Both studies started the infusion
groups off with an abbreviated 3-5 day course of vancomycin. The delivery methods
differed between the studies, Els van Nood et al used nasoduodenal infusion where
Cammarota used colonoscopy. Both studies used 10 weeks as the primary end point for
cure of infection without relapse. The two studies did their statistical analyses on an
intention to treat basis, Cammarota et al did elect to also analyze their data on a per
protocol model as well. According to both of these studies, the difference between the
fecal transplant with the vancomycin and the vancomycin only is statistically significant
with P<0.001 and P<0.0001 for Els van Nood et al and Cammarota et al respectively.
We independently calculated the number needed to treat values for both studies to be
1.58 for Els van Nood et al and 1.57 for Cammaroda et al. The two studies we reviewed
were very similar with regard to statistical power, design, cure rates, and number
needed to treat. They did differ in delivery methods, dosing, and in regard to donor
selection. Figure 2 provides a visual comparison between the percentage of patients in
these two studies who were “cured” for both the fecal transplant with abbreviated
vancomycin treatment and the standard vancomycin only treatment.
Figure 2. Percentage cured at the end of treatment,
comparing the vancomycin group to the fecal
transplant group between the two research papers.

Conclusion
The differences between these studies may have impacted the data - such as the
delivery route of nasoduodenal tube versus colonoscopy. Currently there are some

randomized controlled trials investigating the most efficient route for administration and
as soon as the best route is identified future studies may be able to utilize similar routes
and reduce the error that this may produce in determining efficacy of fecal transplant.
The screening of the donors also differed in the criteria that were used to determine the
eligibility of the donor. A standard protocol for donor selection would help reduce bias as
well as and help to protect against the transmission of pathogens. These two studies
combined included a total of 68 participants for both the infusion and vancomycin
groups. Overall these two studies suggest strongly that fecal microbiota transplant is
superior to vancomycin at treating recurrent C. difficile infection. Given the limited
sample size of these two studies and the potential for the transmission of pathogens
from donor to recipients we feel that more larger scale RCT are warranted before this
very promising treatment option is accepted as a safe effective alternative to the current
standard of antibiotic therapy.
Potential harms of fecal transplant include the inherent risks from the different delivery
methods such as trauma from the insertion of the nasogastric tube or the endoscope for
the colonoscopy. There is the possibility of transmission of infectious diseases but there
has yet to be any documented cases of this so far.
The risk associated with oral vancomycin include nephrotoxicity, hypokalemia, fever,
rash (Stevens-Johnson syndrome), ototoxicity, anaphylaxis, and superinfection.
Both of these studies compare standard vancomycin treatment to an abbreviated
vancomycin in addition to fecal transplant. It will be interesting to see a study that
compares an abbreviated course of vancomycin in addition to fecal transplant to a
stand-alone fecal transplant therapy to further differentiate between the efficacy of the
two treatments. Another area of interest for future studies includes using intensive care
unit patients that were excluded from these two studies, to help determine the
effectiveness of vancomycin versus fecal transplant, since these patients may be more
at risk to develop C. difficile compared to the general population.
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